Alnylam Pharmaceuticals vs United Therapeutics
ALNY and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and UTHR compare
United Therapeutics is the larger company, worth 1.2 times as much as Alnylam Pharmaceuticals ($25.7B against $22.1B).
United Therapeutics scores higher on the StockData Score (10 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | UTHR |
|---|---|---|
| Size and price | ||
| Market cap | $22.1B | $25.7B |
| Share price | $165.00 | $598.72 |
| Change, 1 year | −65.7% | 31.5% |
| Change, 5 years | −11.9% | 196% |
| Beta (5Y) | 0.88 | 0.54 |
| Employees | 2,500 | 1,400 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 21.4× |
| P/S | – | 8.1× |
| P/B | 6.1× | 4.0× (better) |
| EV/EBITDA | – | 15.4× |
| P/FCF | – | 23.5× |
| PEG | – | 0.93 |
| FCF yield | – | 4.3% |
| Fair value | – | $477.00 |
| Margin of safety | – | −25.5% |
| Growth | ||
| Revenue growth (TTM) | – | 2.5% |
| Revenue growth, 5Y average | 49.8% (better) | 16.5% |
| Net income growth (TTM) | 2137% (better) | 5.5% |
| EPS growth (TTM) | – | 9.0% |
| EPS growth, 5Y average | – | 19.3% |
| Profitability | ||
| Gross margin | – | 86.1% |
| Operating margin | – | 44.4% |
| Net margin | – | 41.6% |
| FCF margin | – | 34.6% |
| Return on equity | 127% (better) | 19.3% |
| Return on invested capital | – | 29.7% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 117× |
| Current ratio | 2.48 | 5.73 (better) |
| Altman Z-score | 2.75 | 22.13 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.7% |
| Shareholder yield | 0.00% | 9.7% (better) |
| Ownership | ||
| Held by institutions | 99.8% | 97.4% |
| Held by insiders | 0.49% | 5.9% |
| Insider net buying, 12 months | −$43.6M (better) | −$1.3B |
| Short interest, % of float | 5.8% | 8.9% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- UTHR stock overview
- UTHR income statement
- UTHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.